1. Home
  2. TOVX vs SNOA Comparison

TOVX vs SNOA Comparison

Compare TOVX & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.17

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

N/A

Current Price

$2.43

Market Cap

6.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOVX
SNOA
Founded
2001
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
6.1M
IPO Year
2012
2006

Fundamental Metrics

Financial Performance
Metric
TOVX
SNOA
Price
$0.17
$2.43
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.8M
9.9K
Earning Date
06-19-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
89.07
N/A
EPS
N/A
N/A
Revenue
N/A
$14,288,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.19
52 Week Low
$0.16
$1.77
52 Week High
$1.50
$6.92

Technical Indicators

Market Signals
Indicator
TOVX
SNOA
Relative Strength Index (RSI) 41.68 35.47
Support Level $0.17 $2.30
Resistance Level $0.26 $3.85
Average True Range (ATR) 0.01 0.16
MACD -0.00 -0.02
Stochastic Oscillator 3.91 20.24

Price Performance

Historical Comparison
TOVX
SNOA

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: